| Title |
New development in CAR-T cell therapy
|
|---|---|
| Published in |
Journal of Hematology & Oncology, February 2017
|
| DOI | 10.1186/s13045-017-0423-1 |
| Pubmed ID | |
| Authors |
Zhenguang Wang, Zhiqiang Wu, Yang Liu, Weidong Han |
| Abstract |
Chimeric antigen receptor (CAR)-engineered T cells (CAR-T cells) have yielded unprecedented efficacy in B cell malignancies, most remarkably in anti-CD19 CAR-T cells for B cell acute lymphoblastic leukemia (B-ALL) with up to a 90% complete remission rate. However, tumor antigen escape has emerged as a main challenge for the long-term disease control of this promising immunotherapy in B cell malignancies. In addition, this success has encountered significant hurdles in translation to solid tumors, and the safety of the on-target/off-tumor recognition of normal tissues is one of the main reasons. In this mini-review, we characterize some of the mechanisms for antigen loss relapse and new strategies to address this issue. In addition, we discuss some novel CAR designs that are being considered to enhance the safety of CAR-T cell therapy in solid tumors. |
X Demographics
The data shown below were collected from the profiles of 15 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | 20% |
| Russia | 2 | 13% |
| Saudi Arabia | 1 | 7% |
| Taiwan | 1 | 7% |
| France | 1 | 7% |
| Italy | 1 | 7% |
| Spain | 1 | 7% |
| Comoros | 1 | 7% |
| Unknown | 4 | 27% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 8 | 53% |
| Scientists | 4 | 27% |
| Practitioners (doctors, other healthcare professionals) | 2 | 13% |
| Unknown | 1 | 7% |
Mendeley readers
The data shown below were compiled from readership statistics for 725 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | <1% |
| France | 1 | <1% |
| Germany | 1 | <1% |
| Unknown | 722 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 136 | 19% |
| Researcher | 84 | 12% |
| Student > Ph. D. Student | 82 | 11% |
| Student > Master | 79 | 11% |
| Other | 40 | 6% |
| Other | 84 | 12% |
| Unknown | 220 | 30% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 157 | 22% |
| Medicine and Dentistry | 101 | 14% |
| Agricultural and Biological Sciences | 67 | 9% |
| Immunology and Microbiology | 59 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 23 | 3% |
| Other | 80 | 11% |
| Unknown | 238 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 36. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 November 2023.
All research outputs
#1,087,911
of 24,988,588 outputs
Outputs from Journal of Hematology & Oncology
#53
of 1,274 outputs
Outputs of similar age
#22,079
of 316,572 outputs
Outputs of similar age from Journal of Hematology & Oncology
#2
of 44 outputs
Altmetric has tracked 24,988,588 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,274 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 13.4. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 316,572 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 44 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 97% of its contemporaries.